glp 1 ckd GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease Real-World Evidence for GLP-1 Receptor

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT randomized controlled trial

The human microbiome and its impacts on health

Your voice matters, and we need your help to overturn this decision

Therefore, in the overall benefit - risk assessment, the risk of depression associated with GLP 1RAs is not sufficient to alter existing treatment recommendations [29, 50]

Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis

Distinguishing direct pharmacological anti-inflammatory actions from secondary metabolic improvements requires further mechanistic studies and randomized controlled trials specifically designed to assess inflammatory outcomes as primary endpoints